Mirzaten (Mirtazapine)

Mirtazapine, the active ingredient in Mirzaten, is a noradrenergic and specific serotonergic antidepressant presented as an oral tablet for oral use. It is prescribed for the treatment of major depressive disorder in adult patients, helping to improve mood, sleep and appetite through modulation of neurotransmitter activity.

GNH USA supplies Mirzaten as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets European Union quality standards and is manufactured under strict Good Manufacturing Practice guidelines.

Mirtazapine acts on central noradrenergic and serotonergic pathways and is indicated for depressive disorders. - Major depressive disorder: alleviates depressive symptoms and improves overall mood. - Depression with anxiety symptoms: reduces anxiety and promotes better sleep in patients with mixed features. - Depression with insomnia or loss of appetite: helps restore sleep patterns and stimulates appetite, supporting weight gain where needed.

Mirtazapine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Suicidal thoughts or worsening depression

When prescribing Mirzaten, clinicians should consider several safety measures. - Dose titration: start with a low dose and increase gradually as tolerated. - Monitor weight: significant weight gain may occur during therapy. - Assess for suicidal ideation: especially at treatment initiation or dose changes. - Caution in hepatic impairment: dose adjustment may be required. - Avoid abrupt discontinuation: tapering reduces risk of withdrawal symptoms. - Store at ambient temperature: keep in original container, protect from moisture and light.

Mirtazapine can interact with a variety of medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - MAO inhibitors: concurrent use can cause serotonin syndrome. - Central nervous system depressants (e.g., benzodiazepines, alcohol): may enhance sedation and respiratory depression. - Potent CYP2D6 inhibitors: increase mirtazapine plasma concentrations, raising risk of toxicity.

Moderate Interactions (Monitor Closely): - Other antidepressants (SSRIs, SNRIs, tricyclics): additive serotonergic effects may require monitoring. - Antihistamines: combined use can intensify sedation. - CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce mirtazapine effectiveness.